Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting

NEW ORLEANS, June 05, 2017 (GLOBE NEWSWIRE) — Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced several presentations that highlighted the potential of plazomicin against MDR gram-negative bacteria in multiple settings. Data were presented at the American Society for Microbiology (ASM) Microbe 2017 Annual Meeting being held in New Orleans, LA from June 1 to 5, 2017.